HCA Healthcare (HCA) closed the most recent trading day at $328.80, moving +1.12% from the previous trading session. This change outpaced the S&P 500's 1.11% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.24%.The hospital operator's shares have seen an increase of 0.16% over the last month, surpassing the Medical sector's loss of 2.46% and falling behind the S&P 500's gain of 0.48%.The investment community will be closely monitoring the performance o ...

HCA Healthcare (HCA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this hospital operator have returned +4.4% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Medical - Hospital industry, to which HCA belongs, has gained 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?While media release ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11239 HCA Healthcare, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-3865930 (State or Other Jurisdiction of I ...

Financial Data and Key Metrics Changes - Adjusted EBITDA grew just under 14% in Q4 2023 compared to the prior year, driven by strong revenue growth and solid expense management [13] - Diluted earnings per share, excluding gains on sales, were $5.90, representing a 27% increase over the prior year [30] - For 2024, net income attributable to HCA Healthcare is expected to range between $5.2 billion and $5.6 billion, with diluted earnings per share projected between $19.70 and $21.20 [16][17] Business Line Data and Key Metrics Changes - Same-facility admissions grew 3% year-over-year, equivalent admissions were up 4%, and emergency room visits grew 2% in Q4 2023 [8] - Inpatient and outpatient surgery volumes increased approximately 1%, with cardiac procedures and rehab admissions also showing solid growth [8] - For the full year 2023, same facility admissions grew 3.3%, equivalent admissions grew 4.8%, and emergency room business grew 4.7% [39] Market Data and Key Metrics Changes - Payer mix and acuity levels improved year-over-year, contributing to same-facility revenue growth of 11% in Q4 2023 [8] - Managed care and other admissions grew 6% for the full year on a same-facility basis [39] - Medicare Advantage admissions were roughly up 10% in Q4 2023, consistent with trends throughout the year [57] Company Strategy and Development Direction - The company plans to invest over $2 billion in new capital projects in 2024 to increase capacities and integrate newly acquired facilities [5] - A robust agenda is in place to advance digital capabilities and improve operational management, including integrating revenue cycle and case management functions [9] - The strategic plan includes increasing capital spending to over $5 billion and enhancing the share repurchase program to around $5 billion in 2024 [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to normal seasonality in volumes and noted strong demand for services across diversified markets [24][30] - The company anticipates modest benefits from the two-midnight rule as it ramps up throughout 2024, although no material adjustments have been factored into the guidance yet [121] - Management highlighted the importance of workforce development and training as a top organizational priority moving into 2024 [35] Other Important Information - Bill Rutherford, the CFO, announced his retirement after 34 years with the company, with Mike Marks set to succeed him [21][48] - The company expects cash flow from operations to range between $9.5 billion and $10 billion for 2024 [18] Q&A Session Summary Question: Inquiry about volumes and seasonality - Management confirmed that normal seasonality was observed in Q4 2023, with strong performance across most business categories [24] Question: Supplemental payments details - Management discussed the complexity of supplemental payments and their impact on revenue, noting benefits from new programs in North Carolina and Florida [25][40] Question: Medicare revenue growth - Medicare Advantage admissions grew roughly 10% in Q4 2023, with expectations for continued strong demand in 2024 [57] Question: Impact of the two-midnight rule - Management indicated it is too early to judge the full impact of the two-midnight rule but expects it to benefit patients and the company over time [29][121] Question: Labor supply and hiring outlook - Management reported improvements in turnover and hiring pipelines, with a focus on creating a supportive environment for staff [140][141] Question: Capital expenditure guidance - The company plans to allocate over $5 billion in capital spending for 2024, maintaining a balanced approach across inpatient and outpatient facilities [36][79]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11239 HCA Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3865930 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11239 HCA Healthcare, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-3865930 (State or Other Jurisdiction of I ...